



Alabama Medicaid Agency

501 Dexter Avenue
P.O. Box 5624
Montgomery, Alabama 36103-5624

www.medicaid.state.al.us

e-mail: almedicaid@medicaid.state.al.us

Telecommunication for the Deaf: 1-800-253-0799

1-800-362-1504 (334) 293-5500



BOB RILEY
Governor

CAROL A. HERRMANN, MPH
Commissioner

October 28, 2005

Dear Pharmaceutical Manufacturer:

This correspondence is to provide you with formal written notification of an upcoming meeting of the Alabama Medicaid Pharmacy & Therapeutics (P&T) Committee, to be held on Wednesday, December 14, 2005. This meeting may involve review of one or more of your company's drug products. This meeting will be held at the Alabama State Capitol Auditorium located in Montgomery, AL and will begin at 9:00 a.m. All meetings of this committee are open to the public.

The following is a list of drug classes scheduled for review at this meeting:

DRUG CLASSES	
1. Antidepressants - AHFS 281604	3. Cerebral Stimulants/Agents used for ADD/ADHD To include AHFS 282004 (Amphetamines) and Strattera [®]
2. Anxiolytics, Sedatives and Hypnotics AHFS 282404 - Barbiturates AHFS 282408 - Benzodiazepines AHFS 282492 - Misc. Anxiolytics, Sedatives and Hypnotics	4. Alzheimer's Agents AHFS 120400 (to include Aricept [®] , Cognex [®] , Exelon [®] , Razadyne [®] , Reminyl [®] only) and Namenda [®]

As you may be aware, manufacturers whose products are scheduled for review are allowed the opportunity to provide written clinical comments for distribution to the Medicaid P&T Committee members prior to the meeting. All written comments must be received by Medicaid's Clinical Contractor, *MedMetrics Health Partners* (re: AL Medicaid P&T Support; 100 Century Drive; Worcester, MA 01606), no later than **Wednesday, November 23, 2005**.

Please note: Written comments should be limited to clinical information only and should not contain any reference to cost. Manufacturers must provide 20 copies of written comments upon submission to *MedMetrics*. Failure to abide by all of these requirements upon submission will result in a rejection of the clinical comments in their entirety.

For products slated for P&T review, manufacturers are also allowed the opportunity to make brief (no more than 5 minutes) oral summary presentations of product clinical data to the Medicaid P&T Committee on the day of the meeting. Written notification of your intent to make an oral presentation at this meeting, as well as a one-page summary of the material to be presented, must also be received by *MedMetrics Health Partners* no later than **Wednesday, November 23, 2005**. Oral presentations must also be limited to clinical (non-cost-related) information only.

Please refer to the Medicaid web-site for additional information related to presentations, timelines, clinical comment submissions, and/or submission of volume discounts. If you should have additional questions regarding this notice, or if you have received this letter and are no longer the appropriate contact please contact the Medicaid Pharmacy Program at (334) 242-5050.

Sincerely,

Bakeba R. Thomas
Administrator, Pharmacy Clinical Services